Ya Chee Lim

Dr. Ya Chee Lim


Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 March 2022 in Cancers
Verified
Journal Article
Open access
PDF file
Md. Sanower HossainMd. Sanower Hossain
Md. Sanower Hossain
Hidayah KaruniawatiHidayah Karuniawati
Hidayah Karuniawati
AJAmmar Jairoun
Ammar Jairoun
ZUZannat Urbi
Zannat Urbi
DODer Jiun Ooi
Der Jiun Ooi
MHMuhammad Abdul Hadi
Muhammad Abdul Hadi
Colorectal cancer (CRC) is the second most deadly cancer. Global incidence and mortality are likely to be increased in the coming decades. Although the deaths associated with CRC are very high in high-income countries, the incidence and fatalities related to CRC are growing in developing countries too. CRC detected early is entirely curable by surgery and subsequent medications. However, the recurrence rate is high, and cancer drug resistance increases the treatment failure rate. Access to early diagnosis and treatment of CRC for survival is somewhat possible in developed countries. However, these facilities are rarely available in developing countries. Highlighting the current status of CRC, its development, risk factors, and management is crucial in creating public awareness. Therefore, in this review, we have comprehensively discussed the current global epidemiology, drug resistance, challenges, risk factors, and preventive and treatment strategies of CRC. Additionally, there is a brief discussion on the CRC development pathways and recommendations for preventing and treating CRC.

17 August 2016 in Molecules
Verified
Journal Article
Open access
PDF file
YLYa Chee Lim
Ya Chee Lim
RRRajan Rajabalaya
Rajan Rajabalaya
SLShirley H.F. Lee
Shirley H.F. Lee
KTKushan U. Tennakoon
Kushan U. Tennakoon
QLQuang-Vuong Le
Quang-Vuong Le
SDSheba R David
Sheba R David
The mistletoes, stem hemiparasites of Asia and Europe, have been used as medicinal herbs for many years and possess sophisticated systems to obtain nutrients from their host plants. Although knowledge about ethnomedicinal uses of mistletoes is prevalent in Asia, systematic scientific study of these plants is still lacking, unlike its European counterparts. This review aims to evaluate the literature on Scurrula and Viscum mistletoes. Both mistletoes were found to have anticancer, antimicrobial, antioxidant and antihypertensive properties. Plants from the genus Scurrula were found to inhibit cancer growth due to presence of phytoconstituents such as quercetin and fatty acid chains. Similar to plants from the genus Viscum, Scurrula also possesses TNFα activity to strengthen the immune system to combat cancer. In line with its anticancer activity, both mistletoes are rich in antioxidants that confer protection against cancer as well as neurodegeneration. Extracts from plants of both genera showed evidence of vasodilation and thus, antihypertensive effects. Other therapeutic effects such as weight loss, postpartum and gastrointestinal healing from different plants of the genus Scurrula are documented. As the therapeutic effects of plants from Scurrula are still in exploration stage, there is currently no known clinical trial on these plants. However, there are few on-going clinical trials for Viscum album that demonstrate the functionalities of these mistletoes. Future work required for exploring the benefits of these plants and ways to develop both parasitic plants as a source of pharmacological drug are explained in this article.

7 August 2017 in Cell Communication and Signaling
Verified
Journal Article
Open access
PDF file
GAGahana Advani
Gahana Advani
YLYa Chee Lim
Ya Chee Lim
BCBruno Catimel
Bruno Catimel
DLDaisy Sio Seng Lio
Daisy Sio Seng Lio
NNNadia L. Y. Ng
Nadia L. Y. Ng
HCHeung Cheng
Heung Cheng
C-terminal Src kinase (Csk) and Csk-homologous kinase (Chk) are the major endogenous inhibitors of Src-family kinases (SFKs). They employ two mechanisms to inhibit SFKs. First, they phosphorylate the C-terminal tail tyrosine which stabilizes SFKs in a closed inactive conformation by engaging the SH2 domain in cis. Second, they employ a non-catalytic inhibitory mechanism involving direct binding of Csk and Chk to the active forms of SFKs that is independent of phosphorylation of their C-terminal tail. Csk and Chk are co-expressed in many cell types. Contributions of the two mechanisms towards the inhibitory activity of Csk and Chk are not fully clear. Furthermore, the determinants in Csk and Chk governing their inhibition of SFKs by the non-catalytic inhibitory mechanism are yet to be defined. We determined the contributions of the two mechanisms towards the inhibitory activity of Csk and Chk both in vitro and in transduced colorectal cancer cells. Specifically, we assayed the catalytic activities of Csk and Chk in phosphorylating a specific peptide substrate and a recombinant SFK member Src. We employed surface plasmon resonance spectroscopy to measure the kinetic parameters of binding of Csk, Chk and their mutants to a constitutively active mutant of the SFK member Hck. Finally, we determined the effects of expression of recombinant Chk on anchorage-independent growth and SFK catalytic activity in Chk-deficient colorectal cancer cells. Our results revealed Csk as a robust enzyme catalysing phosphorylation of the C-terminal tail tyrosine of SFKs but a weak non-catalytic inhibitor of SFKs. In contrast, Chk is a poor catalyst of SFK tail phosphorylation but binds SFKs with high affinity, enabling it to efficiently inhibit SFKs with the non-catalytic inhibitory mechanism both in vitro and in transduced colorectal cancer cells. Further analyses mapped some of the determinants governing this non-catalytic inhibitory mechanism of Chk to its kinase domain. SFKs are activated by different upstream signals to adopt multiple active conformations in cells. SFKs adopting these conformations can effectively be constrained by the two complementary inhibitory mechanisms of Csk and Chk. Furthermore, the lack of this non-catalytic inhibitory mechanism accounts for SFK overactivation in the Chk-deficient colorectal cancer cells.

1 January 2020 in Oncology Reviews
Verified
Journal Article
Open access
PDF file
HIHamizah Ibrahim
Hamizah Ibrahim
YLYa Chee Lim
Ya Chee Lim
Colorectal cancer (CRC) is one of the leading causes of cancer-related death worldwide. Despite progress in treatment of cancers, CRC with KRAS mutations are resistant towards anti-EGFR treatment. MicroRNAs have been discovered in an exponential manner within the last few years and have been known to exert either an onco-miRNA or tumor suppressive effect. Here, the various roles of microRNAs involved in the initiation and progression of KRAS-regulated CRC are summarized. A thorough understanding of the roles and functions of the plethora of microRNAs associated with KRAS in CRC will grant insights into the provision of other potential therapeutic targets as well as treatment. MicroRNAs may also serve as potential molecular classifier or early detection biomarkers for future treatment and diagnosis of CRC.

7 July 2022 in Frontiers in Bioscience-Landmark
Verified
Journal Article
Open access
PDF file
DDDatul Damit
Datul Damit
RPRavi Patnaik
Ravi Patnaik
LCLi Ling Chaw
Li Ling Chaw
SLShir Kiong Lu
Shir Kiong Lu
PTPemasiri Upali Telisinghe
Pemasiri Upali Telisinghe
YLYa Chee Lim
Ya Chee Lim
Introduction: Colorectal cancer (CRC) is one of the most common cancer types, with rising incidence due to imbalanced lifestyle and dietary habit. Association between CRC cases and KRAS mutation has been established recently. Brunei Darussalam, located within the Borneo island, is of diverse ethnicity which could represent the genome of Southeast Asia population. Our study, for the first time, determined the survival outcome of metastatic colorectal cancer (mCRC) and established the link with KRAS mutation by modelling the population in Brunei Darussalam. Methods: We collected data of 76 metastatic CRC (mCRC) patients undergoing treatment at The Brunei Cancer Centre, the national centre for cancer treatment in Brunei. These patients were diagnosed with Stage 4 CRC between 1 January 2013 and 31 December 2017. Age, gender, ethnicity, date of diagnosis, site of primary tumour, metastatic sites and molecular analysis of KRAS mutation status (either KRAS mutated or KRAS wild-type) of tumour were recorded. The survival outcomes of these mCRC patients were analysed. Results: The end of this study period recorded 73.1% deceased mutant KRAS mCRC patients and 46.0% deceased wild-type KRAS mCRC patients, contributing to death rates of 45.2% and 54.8%, correspondingly. Chi-squared analysis showed a significant difference between the survival outcomes of wild-type KRAS and mutant KRAS mCRC patients (p-value = 0.024). Conclusions: There is a significant difference between the survival outcomes of wild-type KRAS and mutant KRAS mCRC patients in the Brunei population. In addition, we found that mutations in codon 12 of KRAS gene on mutant KRAS mCRC patients have shorter survival median periods than those with mutations within codon 13 of KRAS gene. This is the first study in Brunei Darussalam to analyse both the survival outcomes of mCRC patients and those of mutant KRAS mCRC patients.

1 March 2022 in Current Nutrition & Food Science
Verified
Journal Article
Closed access
PDF file
SDSheba R David
Sheba R David
MMMiza Syazwina Mohammad
Miza Syazwina Mohammad
YLYa Chee Lim
Ya Chee Lim
RRRajan Rajabalaya
Rajan Rajabalaya
Background: The incorporation of oils in the diet may have promoting or inhibitory effects on Colorectal Cancer (CRC). In this study, azoxymethane (AOM) was used to mimic CRC in rats, and the effect of sunflower oil on cancer progression in the colon of the rats was tested. Objective: This study was conducted to investigate the effect of sunflower oil on preneoplastic cancer properties of the colonic mucosal surface of tumors and the aberrant crypt foci (ACF). Methods: Six-week-old Sprague-Dawley male rats were randomized into 4 groups of 6 rats each, namely naïve, positive control, negative control, and sunflower oil-fed. CRC was induced by AOM by subcutaneous injection of 20 mg/kg. After CRC induction, the rats were given the respective treatment of either basal diet (naïve group), 10 mg/kg indomethacin (positive control), 0.9 % saline (negative control), or 7 % sunflower oil (experimental group) daily by oral gavage for 42 days. Rats were sacrificed by cervical dislocation; colon samples were visually observed for any tumors on the colonic mucosal surface and evaluated for ACF; histopathological examinations were also performed. Results: The mean body weights of the rats were similar in all groups as per one-way ANOVA. A total of 3 ACF were found in the negative group, while none were observed in other groups. The crypts appeared regular with circular luminal openings and were closely packed together in the naïve group. Crypts in the positive and treated group had a similar appearance to the naïve group. Conclusion: Sunflower oil inhibition of the preneoplastic cancer ACF properties were tested but were found to be insignificant when administered during CRC treatment or management. However, long-term experiments with a greater number of days will yield better development of tumor and ACF development and will be useful in identifying the molecular mechanism.